1068 related articles for article (PubMed ID: 24164940)
1. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
Angthong C; Rodjanawijitkul S; Samart S; Angthong W
Acta Orthop Traumatol Turc; 2013; 47(5):318-22. PubMed ID: 24164940
[TBL] [Abstract][Full Text] [Related]
2. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
[TBL] [Abstract][Full Text] [Related]
3. Comment on: Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
Gogna P; Mukhopadhyay R; Jairath V
Acta Orthop Traumatol Turc; 2014; 48(4):472-3. PubMed ID: 25230275
[No Abstract] [Full Text] [Related]
4. Preoperative bone health assessment and optimization in spine surgery.
Anderson PA; Kadri A; Hare KJ; Binkley N
Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
[TBL] [Abstract][Full Text] [Related]
5. What if the silent disease comes with the reality? Comment on: Prevalence of bone mineral density testing and osteoporosis management following low-and high-energy fractures.
Güngör HR; Ök N
Acta Orthop Traumatol Turc; 2015; 49(2):224. PubMed ID: 26012948
[No Abstract] [Full Text] [Related]
6. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
[TBL] [Abstract][Full Text] [Related]
8. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
Lim JS; Jin SH; Kim SB; Lee JI
J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
11. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
12. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
14. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
[TBL] [Abstract][Full Text] [Related]
15. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
16. Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.
Bruyere O; Varela AR; Adami S; Detilleux J; Rabenda V; Hiligsmann M; Reginster JY
Eur J Epidemiol; 2009; 24(11):707-12. PubMed ID: 19728118
[TBL] [Abstract][Full Text] [Related]
17. Variation in bone mineral density by anatomical site in patients with proximal humeral fractures.
Wilson J; Bonner TJ; Head M; Fordham J; Brealey S; Rangan A
J Bone Joint Surg Br; 2009 Jun; 91(6):772-5. PubMed ID: 19483231
[TBL] [Abstract][Full Text] [Related]
18. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
Kaji H; Yamauchi M; Chihara K; Sugimoto T
Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and vertebral fractures in men.
Legrand E; Chappard D; Pascaretti C; Duquenne M; Rondeau C; Simon Y; Rohmer V; Basle MF; Audran M
Osteoporos Int; 1999; 10(4):265-70. PubMed ID: 10692973
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of hip fracture patterns using areal bone mineral density in the proximal femur.
Hey HW; Sng WJ; Lim JL; Tan CS; Gan AT; Ng JH; Kagda FH
Arch Orthop Trauma Surg; 2015 Dec; 135(12):1647-53. PubMed ID: 26391986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
